Intra-Cellular Therapies' shares saw a significant increase after resolving a patent dispute with Sandoz regarding their antipsychotic medication, Caplyta. This settlement allows Sandoz to develop a generic version of the drug, which is expected to increase market competition.

Sandoz had submitted an abbreviated new drug application, indicating their intention to enter the market with a generic alternative. This development is important for both companies, as it provides opportunities for Sandoz and potentially expands patient access to Caplyta.

Investor optimism regarding the future of Intra-Cellular's product is reflected in the performance of their stock, considering the changing landscape of generic pharmaceuticals.